Strainprint Technologies, Gynica launch next phase of cannabis study to treat endometriosis symptoms
Strainprint Technologies Ltd, leading demand-side cannabis data and analytics company, launched the next stage of the much-anticipated clinical trial with Israeli based research group Gynica to develop a product formulation to treat endometriosis and its symptoms. This phase will include asking endometriosis sufferers in Canada and Israel to complete an anonymous, comprehensive custom questionnaire about how they use cannabis to treat their symptoms.
Strainprint with researchers at Gynica, a leader in cannabis-based solutions for women’s health, in late 2018 to conduct the world’s first international clinical study on the use of cannabis to treat endometriosis. The study will leverage Strainprint’s database of patient reported outcomes among those who use cannabis to treat endometriosis, which, along with the results of this questionnaire, will inform the formulation of a cannabis-based product which will be clinically validated and then available for purchase.
Endometriosis affects approximately 1 in 10 women (and people assigned female at birth) and it is a condition with limited understanding and treatment options.
“180 million people worldwide experience severe pain daily as a result of tissue similar to the uterine lining migrating to other organs inside the body, causing debilitating pain, infertility, fatigue, gastrointestinal and/or bladder symptoms,” says Gynica’s professor Moshe Hod, president of the European Association of Perinatal Medicine and professor of Obstetrics and Gynecology at Tel Aviv University medical school. “Our objective is to recruit suffering candidates to explore cannabis as a viable therapy in the hopes of developing improved diagnostics and treatments to those who are